Use of stem cells from mismatched related donors

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 419-422

  Aversa, Franco ^a   Martelli, Massimo M ^a   Reisner, Yair ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DIMETHYLBUSULFAN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW TRANSPLANTATION; DONOR; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SHORT SURVEY; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; WHOLE BODY RADIATION;

EID: 0030732728     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00010     Document Type: Short Survey

References (30)

1. Oudshoorn M, van Leeuwen A, Zanden HGM, van Rood JJ: Bone marrow donors worldwide: a successful exercise In international cooperation. Bone Marrow Transplant 1994, 14:3-8.
2. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, Bearman SI, Anasetti C, Petersdorf EW, Mickelson EM, et al.: Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991, 51:443-447.
3. Anasetti C, Hansen J: Bone marrow transplantation from HLA-partially matched related donors and unrelated volunteer donors. In Bone Marrow Transplantation. Edited by Forman SJ, Blume KG, Thomas ED. Boston: Blackwell Scientific; 1994, 665-679.
4. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, et al.: Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989, 320:197-204.
5. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA: Effect of HLA-incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990, 29:79-91.
6. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, et al.: Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985, 313:765-771.
7. Ash RC, Horowitz MM, Gale RP, van Bekkum DW, Casper JT, Gordon-Smith EC, Henslee-Downey PJ, Kolb HJ, Lowenberg B, Masaoka T, et al.: Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T-cell depletion. Bone Marrow Transplant 1991, 7:443-452.
8. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, Hodes MZ, Good RA, O'Reilly RJ: Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow fractionated by soybean agglutinin and sheep red blood cells. Blood 1983, 61:341-348. This paper confirms the role of an extensive T-cell depletion in preventing severe acute and chronic GVHD in patients with SCID receiving a bone marrow transplant from a full-haplotype mismatched related donor.
9. Reisner Y, Lapidot T, Singer TS, Schwartz E: The host barrier in animal models of T-cell depleted allogeneic bone marrow transplantation. Serono Symposia Review 1988, 13:37-47.
10. Reisner Y, Kirkpatrick D, Dupont B, Kapoor NK, Pollack MS, Good RA, O'Reilly RJ: Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981, 2:327-331.
11. O'Reilly RJ, Kernan NA, Cunningham I, Brochstein J, Keever C, Small T, Bordignon C: T-cell depleted marrow transplants for the treatment of leukemia. In Bone Marrow Transplantation: Current Controversies. Edited by Gale RP and Champlin RE. New York: Alan R Liss; 1989:477-493.
12. Terenzi A, Aversa F, Albi N, Galandrini R, Dembech C, Velardi A, Martelli MF: Residual clonable host cell detection for predicting engraftment of T-cell depleted BMTs. Bone Marrow Transplant 1993, 11:357-361.
13. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ: Graft rejection in recipients of T-cell depleted HLA nonidentical transplants for leukemia: Identification of host derived anti-donor allocytotoxic T-lymphocytes. Transplantation 1987, 43:482-487.
14. Reisner Y, Martelli MF: Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells, Immunol Today 1995, 16:437-440. The authors discuss how the problem of graft rejection in the mismatched setting may be overcome by intensification of the conditioning protocol in conjunction with a major increase in the dose of transplanted stem cells.
15. Schwartz E, Lapidot T, Dalia G, Singer T, Reisner Y: Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors. J Immunol 1987, 138:460-465.
16. Lapidot T, Singer TS, Salomon O, Terenzi A, Schwartz E, Reisner Y: Booster irradiation to the spleen following total body irradiation: a new immunosuppressive approach for allogeneic bone marrow transplantation. J Immunol 1988, 141:2619-2624.
17. Cobbold SP, Martin G, Quin S, Waldman H: Monoclonal antobodies to promote marrow engraftment and tissue graft tolerance. Nature 1986, 323:164-166.
18. Lapidot T, Terenzi A, Singer TS, Salomon O, Reisner Y: Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 1989, 73:2025-2032.
19. Terenzi A, Lubin I, Lapidot T, Salomon O, Faktorowich Y, Rabi I, Martelli MF, Reisner Y: Enhancement of T-cell depleted bone marrow allografts in mice by thiotepa. Transplantation 1990, 50:717-720.
20. Bachar-Lustig E, Rachamim N, Hong-Wei Li, Lan F, Reisner Y: Megadose of T-cell depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nature Med 1995, 12:1268-1273. This paper further demonstrated in an experimental mouse model that escalation of bone marrow doses by four- to fivefold led to full donor-type chimerism even in sublethally irradiated animals.
21. Soiffer RJ, Mauch P, Tarbell NJ, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Murrey CI, Coral F, Bosserman L, et al.: Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T-cell-depleted allogeneic marrow. Bone Marrow Transplant 1991, 7:23-33.
22. Arthur C, Hows J, Jones L, Apperley J, Hale G, Waldmann H, Economou K, Gordon-Smith E, Goldman J: Marrow transplantation in absence of a HLA identical donor: the use of in vivo and ex vivo monoclonal antibodies. Bone Marrow Transplant 1987, 2:137.
23. Friedrich W, Ebell W, Blutters-Sawatzki R, Wiesneth M, Goldmann SF, Kubarek B: In vivo use of monoclonal antibody for conditioning in T-cell depleted HLA-non-identical BMT. Bone Marrow Transplant 1987, 2:145.
24. Bozdech MJ, Sondel PM, Trigg ME, Longo W, Kohler PC, Flynn B, Billing R, Anderson SA, Hank JA, Hong R: Transplantation of HLA-haploidentical T-cell depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Exp Hematol 1985, 13:1201-1210.
25. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Jacucci R, Zei T, Martelli MP, Gambelunghe C, et al.: Successful engraftment of T-cell depleted haploidentical "three loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow Inoculum. Blood 1994, 84:3948-3955. This was the first clinical study confirming that in humans, as in mice, the stem cell dose, in combination with a highly immunosuppressive and myeloablative conditioning, plays a crucial role in overcoming the HLA-histocompatibility barriers.
26. Reisner Y, Friederich W, Fabian I: A shorter procedure for preparation of E-rosette depleted bone marrow for transplantation. Transplantation 1986, 42:312-316.
27. Ross SR, McTavish D, Faulds D: Fludarabine: a review of its pharmacological properties and therapeutic potential in malignancy. Drugs 1993, 45:737-759.
28. Terenzi A, Aversa F, Perruccio K, Aristei C, Chionne F, Latini P, Martelli MF: Efficacy of fludarabine as immunosuppressor for bone marrow transplantation conditioning [abstract]. Blood 1996, 88(suppl 1): 2373.
29. Martelli MF, Aversa F, Velardi A, Cunningham I, Tabilio A, Terenzi A, Falzetti F, Felicini R, Ruggeri L, Albi N, et al.: New tools for crossing the HLA barrier: fludarabine and megadose stem cell transplants [abstract]. Blood 1996, 88(suppl 1):1924.
30. Albi N, Ruggeri L, Aversa F, Merigiola C, Tosti A, Tognellini R, Grossi CE, Martelli MF, Velardi A: Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "three loci" HLA-incompatible bone marrow transplantation. Blood 1996, 87:3993-4000. The authors demonstrated that in mismatched transplant recipients, in addition to conventional natural killer cells, two potential antitumor effectors were detected: KIR cytotoxic T cells and donor-versus-recipient alloreactive natural killer cells. They can provide a selective graft-versus-leukemia effect in absence of graft-versus-host reaction.